里昂指出，行业基本面持续复苏，7月院内处方量环比提升，随着更多创新药放量，第三季行业盈利有 望实现显著增长，加上美债不确定性可能促使资金重新配置，进一步改善创新药资产流动性，相信行业 拐点已过，未来将迎来盈喜等正面催化剂。 该行偏好领先大型药厂，短期而言避开过度依赖生物仿制药的公司。该行选股包括石药集团(01093)、 新诺威(300765.SZ)、翰森制药(03692)、爱尔眼科(300015.SZ)、恒瑞医药(01276,600276.SH)、康方生物 (09926)、中生制药(01177)、国药控股(01099)、康哲药业(00867)、大参林(603233.SH)、华东医药 (000963.SZ)、泰格医药(03347)及药明康德(02359)。 智通财经APP获悉，里昂发布研报称，中国医疗健康行业流动性及基本面持续改善，维持对医疗健康板 块正面看法，指出美国就业数据疲软或市场对下半年货币宽松预期急升温，预示着行业下半年改善前 景，相信特朗普再提最惠国药品定价政策及安徽启动生物类似药集中采购，对行业影响则相对有限。 ...

Group 1: Top Net Buy/Sell Companies - The top net buy company is BYD Company Limited (1211.HK) with a net buy amount of 14.245 billion CNY, representing a significant increase of 122,586,413 shares[8] - The second highest net buy is the Tracker Fund of Hong Kong (2800.HK) with a net buy amount of 6.866 billion CNY, with 274,875,500 shares acquired[8] - The top net sell company is China Mobile Limited (0941.HK) with a net sell amount of -2.151 billion CNY, reflecting a decrease of 25,038,050 shares[9] Group 2: Industry Distribution of Net Buy/Sell - The financial sector shows strong activity with major net buys from China Construction Bank (0939.HK) and China Life Insurance (2628.HK), totaling 3.020 billion CNY and 2.416 billion CNY respectively[8] - The consumer discretionary sector is also prominent, with significant net buys from BYD and Li Auto (2015.HK), amounting to 14.245 billion CNY and 2.137 billion CNY respectively[8] - In contrast, the telecommunications sector, led by China Mobile, shows a notable net sell, indicating a potential shift in investor sentiment[9] Group 3: Active Stocks - Meituan-W (3690.HK) is the most active stock in the Shanghai-Hong Kong Stock Connect with a total trading volume of 4.049 billion CNY and a net buy of 1.196 billion CNY[19] - Alibaba Group (9988.HK) follows closely with a trading volume of 3.790 billion CNY and a net buy of 0.654 billion CNY[19] - Xiaomi Corporation (1810.HK) also shows strong activity with a trading volume of 3.694 billion CNY and a net buy of 0.368 billion CNY[19]

Summary of Conference Call Notes Company and Industry Overview - **Company**: Anke Bio (安科生物) - **Industry**: Pharmaceutical and Biotechnology, focusing on innovative drugs and gene therapy Key Points and Arguments 1. **Pharmaceutical Sector Performance**: The pharmaceutical sector has shown strong excess returns despite market pressures, with innovative drugs and traditional Chinese medicine performing particularly well, indicating a sustained bull market in pharmaceuticals [2][3] 2. **Focus on Innovative Drugs**: The clear future direction for the pharmaceutical industry is innovative drugs, with a focus on leading companies and those with significant catalysts or market potential [4][5] 3. **Anke Bio's CD7 CAR-T Therapy**: Anke Bio's CD7 CAR-T therapy for T-cell lymphoma and leukemia shows a total response rate (ORR) of 84.6% and a complete response rate of 77%, with promising durability [2][9] 4. **Market Potential for CD7 CAR-T**: The domestic market for relapsed/refractory T-cell lymphoma and leukemia is estimated at 2.1 billion yuan, with potential expansion to 5 billion yuan if additional indications are successful [10] 5. **Gene Therapy Developments**: AAV gene therapy in ophthalmology has advantages such as immune evasion and lower dosage requirements, with significant projects like Regenexbile and AbbVie’s RGX-314 expected to complete key trials by 2025 [14][15] 6. **Investment Recommendations**: Recommended stocks include Kangfang Biotech, Shanghai Pharmaceuticals, Anke Bio, and others, with a focus on companies with strong short-term performance or potential rebounds [6][7] 7. **Valuation of Anke Bio**: Anke Bio's current market cap is approximately 20 billion yuan, with potential to double to 40 billion yuan as the innovative drug segment is not fully valued [12] 8. **Innovative Pipeline**: Anke Bio has multiple innovative pipelines, including HER2 monoclonal antibodies and PD-L1/4-1BB bispecific antibodies, indicating a broad future development outlook [11][23] Additional Important Insights 1. **Clinical Trial Progress**: Anke Bio's CD7 CAR-T therapy is leading in domestic clinical progress, with significant catalysts expected soon [9] 2. **Safety and Efficacy**: The adverse reactions for Anke Bio's therapy are comparable to existing CAR-T therapies, making it a viable option for patients [10][20] 3. **Global Gene Therapy Landscape**: The AAV gene therapy field is seeing significant interest from major pharmaceutical companies, with a focus on rare diseases and expanding into common diseases [18][22] 4. **Emerging Companies**: Companies like Kanghong Pharma and TEBIO are making notable advancements in AAV gene therapy, particularly in ophthalmology [19][22] This summary encapsulates the key insights from the conference call, highlighting the performance and future potential of Anke Bio and the broader pharmaceutical industry.

8月5日，港股早盘高开，创新药"新势力"港股通创新药ETF（520880）场内价格一度涨近2%，现涨 1.16%，再现宽幅溢价，实时溢价率达0.5%，显示买盘资金信心颇足。 | 序号 | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | --- | | 1 | 6852 | 亚盛医药 - B | 1005 | 76.800 | 3:450 | 4.70% | | 2 | 6966 | 诺诚健华 | 110000 | 18.540 | 0.690 | 3.87% | | 3 | 1801 | 信达生物 | per | 95.800 | 2.900 | 3.12% | | 4 | 6160 | 百济神州 | 5 | 187.800 | 5.200 | 2.85% | | 5 | 9926 | 康方生物 | mr | 156.300 | 4.200 | 2.76% | | 6 | 2162 | 康诺亚 - B | SA | 63.400 | 1.550 | 2.51% | | 7 | 9688 | 再鼎医药 | 800 | 3 ...

该行偏好领先大型药厂，短期而言避开过度依赖生物仿制药的公司。该行选股包括石药集团、新诺威、 翰森制药、爱尔眼科、恒瑞医药、康方生物、中生制药、国药控股、康哲药业、大参林、华东医药、泰 格医药及药明康德。 里昂发表研究报告指，中国医疗健康行业流动性及基本面持续改善，维持对医疗健康板块正面看法。该 行指出，行业基本面持续复苏，7月院内处方量按月提升，随着更多创新药放量，第三季行业盈利有望 实现显著增长，加上美债不确定性可能促使资金重新配置，进一步改善创新药资产流动性，相信行业拐 点已过，未来将迎来盈喜等正面催化剂。 ...

Group 1 - The core viewpoint emphasizes optimism towards the long-term development of innovative drugs in China, driven by domestic engineer advantages, rich clinical resources, and supportive policies [2] - The innovative drug industry is transitioning into a 2.0 era, with significant improvements in quality and a strong pipeline expected to enhance profitability and cash flow for domestic companies [2][5] - The market for innovative drugs is experiencing a revival in investment and financing activities, particularly in the second quarter of the year, indicating a positive shift from previous years [2][4] Group 2 - Recent policies related to commercial health insurance are anticipated to accelerate medical payment reforms, alleviating supply-demand conflicts and promoting domestic innovation [3] - The introduction of childcare subsidies is expected to stimulate consumption related to infants and young children, addressing long-term demographic pressures [3] - Increased fiscal policies in the second half of the year are likely to boost market interest in domestic medical equipment stocks [3] Group 3 - The Hong Kong stock market has shown a collective rise, with the Hong Kong Innovative Drug ETF (159570) experiencing significant net inflows and reaching a record scale of over 12 billion [4] - The ETF's underlying index is fully focused on the innovative drug industry, with a notable increase of over 109% in the past year, outperforming other indices [7][8] - Major pharmaceutical companies in China are actively engaging in overseas licensing deals, indicating a pivotal moment for the realization of innovative drug pipeline values [5][6]

Group 1 - The core viewpoint of the news highlights the ongoing bullish trend in the innovative drug sector, driven by significant business development (BD) projects and active trading in related ETFs [1][2][3][4] - The Hong Kong stock market saw a slight increase in major indices, with a notable rise in biopharmaceutical stocks, indicating strong market interest in this sector [1] - Key innovative drug companies such as Hengrui Medicine, CSPC Pharmaceutical, and Lepu Biopharma have secured substantial overseas licensing agreements, which are expected to generate significant revenue [2][3] Group 2 - The innovative drug sector is anticipated to maintain momentum through 2025, supported by major academic conferences that will catalyze market interest [3] - There is a focus on emerging technologies and unmet clinical needs, with specific attention to areas such as dual-target and multi-target therapies, small nucleic acids, and next-generation immuno-oncology drugs [3] - The Hong Kong Innovative Drug Select ETF (520690) tracks a pure innovative drug index, which has shown impressive growth, making it a focal point for investors [4]

Group 1 - The Hong Kong Innovation Drug ETF (513120) has shown strong performance, with a recent increase of 1.90% and a total scale reaching 15.257 billion [1] - The ETF has attracted significant capital inflow, accumulating 354 million over the last five trading days, and has a one-year net value increase of 127.14% [1][2] - The index tracks up to 50 listed companies involved in innovative drug research, with a high concentration in biopharmaceuticals and chemical pharmaceuticals, accounting for 92.5% of the index [2] Group 2 - The top ten weighted stocks in the index account for 70.59%, including companies like 康方生物 (09926) and 信达生物 (01801) [2] - The innovation drug sector is entering a phase of "clinical value reassessment," shifting from a narrative-driven valuation to a profit-driven approach, indicating long-term investment potential [2] - The sector is expected to maintain its growth due to policy support, enhanced global competitiveness, and successful commercialization [3] Group 3 - The ETF allows T+0 trading, enhancing liquidity and efficiency for investors [3]

Core Viewpoint - The Hong Kong stock market is showing strong performance in the innovative drug sector, with significant price increases in related ETFs and stocks, driven by expectations of interest rate cuts by the Federal Reserve [1][3]. Group 1: Market Performance - The Hong Kong stock market opened higher on August 5, with the innovative drug ETF (520880) rising nearly 2% at one point and currently up 1.16%, indicating strong buying confidence [1]. - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has increased by 101.58% year-to-date as of July 31, significantly outperforming the Hang Seng Index (23.50%) and the Hang Seng Tech Index (22.05%) by 78.08 and 79.53 percentage points, respectively [6]. - Individual stocks in the innovative drug sector have also shown strong gains, with notable increases such as Ascentage Pharma-B up nearly 5% and several others like Innovent Biologics and BeiGene rising over 3% [4]. Group 2: Economic Indicators - The U.S. non-farm payrolls increased by 73,000 in July, significantly below the expected 104,000, marking the smallest increase since October of the previous year, which has led to heightened expectations for interest rate cuts by the Federal Reserve [2][3]. - Goldman Sachs predicts that the Federal Reserve will begin a series of three consecutive 25 basis point rate cuts starting in September, with the possibility of a 50 basis point cut if unemployment rises further [3]. Group 3: Industry Outlook - The innovative drug sector is expected to benefit significantly from the anticipated interest rate cuts, as these stocks are sensitive to interest rate changes, prompting market participants to position themselves ahead of potential valuation increases for drug companies [3]. - CITIC Securities highlights that China's innovative drug development has made significant progress, and recent measures to support high-quality development in this sector will further enhance growth prospects [3].

Group 1 - The core viewpoint is that Hong Kong's innovative drug concept stocks have strengthened, with companies like Innovent Biologics, BeiGene, and CanSino Biologics rising over 2% [1] - The Hong Kong innovative drug-related ETFs have increased by approximately 2% due to the rise of heavy-weight stocks [1] Group 2 - The current prices and changes of relevant ETFs are as follows: Hong Kong Innovative Drug ETF (code: 520880) is priced at 1.230 with an increase of 0.023 (1.91%); Hong Kong Innovative Drug Select ETF (code: 520690) is priced at 0.996 with an increase of 0.020 (2.05%) [2] - Analysts indicate that multinational pharmaceutical companies have significantly increased their procurement of innovative drug patents in China this year, with the procurement amount from January to May nearing the total for the entire year of 2024, demonstrating the competitiveness of China's innovative drugs in the international market [2] - The trend of large multinational pharmaceutical companies accelerating the procurement of innovative drug patents from China is expected to continue in the medium to long term [2]